Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol

Journal of Crohn's and Colitis

Volumn 6, Issue 9, 2012, Pages 905-912

  Smith, Melissa A ^a   Blaker, Paul ^a   Marinaki, Anthony M ^a   Anderson, Simon H ^a   Irving, Peter M ^a   Sanderson, Jeremy D ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

6 Mercaptopurine; Allopurinol; Azathioprine; Inflammatory bowel disease; Thioguanine nucleotides

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; MERCAPTOPURINE;

ADULT; AGED; ALOPECIA; ARTHRALGIA; ARTICLE; BLOOD ANALYSIS; BONE MARROW TOXICITY; CELL VOLUME; CONTROLLED STUDY; CROHN DISEASE; DRUG INDICATION; DRUG POTENTIATION; DRUG TOLERANCE; DRUG TREATMENT FAILURE; ENTERITIS; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL ERROR; MYALGIA; NAUSEA; NEUTROPHIL COUNT; PRESCRIPTION; PRIORITY JOURNAL; RASH; REMISSION; RESPIRATORY TRACT INFECTION; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; ULCERATIVE COLITIS; VOMITING;

6-MERCAPTOPURINE; ADULT; AGED; AGED, 80 AND OVER; ALLOPURINOL; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG THERAPY, COMBINATION; DRUG-INDUCED LIVER INJURY; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; MIDDLE AGED; PURINE NUCLEOTIDES; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THIOGUANINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865713570     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2012.02.007     Document Type: Article

References (27)

1. Cosnes J., Nion-Larmurier I., Beaugerie L., Afchain P., Tiret E., Gendre J.P. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005, 54:237-241.
2. Elion G.B. The purine path to chemotherapy. Science 1989, 244:41-47.
3. Chocair P., Duley J., Simmonds H.A., Cameron J.S., Ianhez L., Arap S., et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993, 342:83-84.
4. Chrzanowska M., Krzymanski M. Determination of 6-thioguanine and 6-methylmercaptopurine metabolites in renal transplantation recipients and patients with glomerulonephritis treated with azathioprine. Ther Drug Monit 1999, 21:231-237.
5. Dubinsky M.C., Yang H., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002, 122:904-915.
6. Ansari A., Elliott T., Baburajan B., Mayhead P., O'Donohue J., Chocair P., et al. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28:734-741.
7. Sparrow M.P., Hande S.A., Friedman S., Lim W.C., Reddy S.I., Cao D., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22:441-446.
8. Sparrow M.P., Hande S.A., Friedman S., Cao D., Hanauer S.B. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007, 5:209-214.
9. Ansari A., Patel N., Sanderson J., O'Donohue J., Duley J.A., Florin T.H. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010, 31:640-647.
10. Breen D.P., Marinaki A.M., Arenas M., Hayes P.C. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 2005, 11:826-833.
11. Dervieux T., Boulieu R. Simultaneous determination of 6-thioguanine and methyl 6-mercaptopurine nucleotides of azathioprine in red blood cells by HPLC. Clin Chem 1998, 44:551-555.
12. Ansari A., Arenas M., Greenfield S.M., Morris D., Lindsay J., Gilshenan K., et al. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28:973-983.
13. Colombel J.F., Sandborn W.J., Reinisch W., Mantzaris G.J., Kornbluth A., Rachmilewitz D., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
14. Sokol H., Seksik P., Carrat F., Nion-Larmurier I., Vienne A., Beaugerie L., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
15. Vermeire S., Noman M., Van A.G., Baert F., D'Haens G., Rutgeerts P.J. The effectiviness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56(9):1226-1231.
16. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010, CD000545.
17. Butler R., Morris A.D., Belch J.J., Hill A., Struthers A.D. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000, 35:746-751.
18. Marinaki A.M., Duley J.A., Arenas M., Ansari A., Sumi S., Lewis C.M., et al. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids 2004, 23:1393-1397.
19. Hindorf U., Johansson M., Eriksson A., Kvifors E., Almer S.H. Mercaptopurine treatment should be considered in azathioprine intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009, 29:654-661.
20. Korelitz B.I., Reddy B., Bratcher J. Desensitization of patients with allergic reactions to immunosuppressives in the treatment of inflammatory bowel disease. Expert Opin Drug Saf 2010, 9:379-382.
21. Lee H.Y., Ariyasinghe J.T., Thirumoorthy T. Allopurinol hypersensitivity syndrome: a preventable severe cutaneous adverse reaction?. Singapore Med J 2008, 49:384-387.
22. Halevy S., Ghislain P.D., Mockenhaupt M., Fagot J.P., Bouwes Bavinck J.N., Sidoroff A., et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008, 58:25-32.
23. Somkrua R., Eickman E.E., Saokaew S., Lohitnavy M., Chaiyakunapruk N. Association of HLA-B5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med Genet 2011, 12:118.
24. Atzori L., Pinna A.L., Mantovani L., Ferreli C., Pau M., Mulargia M., et al. Cutaneous adverse drug reactions to allopurinol: 10year observational survey of the Dermatology Department - Cagliari University (Italy). J Eur Acad Dermatol Venereol 2011, [Epub ahead of print]. 10.1111/j.1468-3083.2011.04313.x.
25. Blaker P., Arenas M., Fairbanks L., Irving P., Marinaki A.M., Sanderson J.D. A biochemical mechanism for the role of allopurinol in TPMT inhibition. Gastroenterology 2011, 140(Suppl. 1):Tu1214.
26. Bell B.A., Brockway G.N., Shuster J.J., Erdmann G., Sterikoff S., Bostrom B., et al. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group). Pediatr Blood Cancer 2004, 43:105-109.
27. Bradford K., Shih D.Q. Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol 2011, 17:4166-4173.